EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

VLX600, an anticancer iron chelator, exerts antimicrobial effects on Mycobacterium abscessus infections

Jaehun Oh iD, Seaone Choi, Hyejun Seo, Dong Hyun Kim, Hyelin Kim, Duhyung Lee, Junghwa Jang, Sangkwon Jung, Ju-Young Lee, Ziyun Kim, Jae-Joon Yim, Nakwon Kwak iD und 1 weitere

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.00719-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Jaehun Oh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous, Anti-Bacterial Agents, Iron Chelating Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF), SNUBH Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium abscessus presents significant clinical challenges due to its intrinsic and acquired resistance to antibiotics, resulting in prolonged treatments and poor patient outcomes. Addressing the urgent need for novel therapeutics, this study explores the antimicrobial potential of VLX600, originally developed as an anticancer agent, against M. abscessus . Screening a library of 3,200 clinically evaluated compounds identified VLX600 as a potent antimicrobial with minimal cytotoxicity. VLX600 demonstrated inhibitory effects against various strains of M. abscessus with minimum inhibitory concentrations of 4 µg/mL–16 µg/mL. It also remained effective in intracellular M. abscessus in host cells and exhibited broad-spectrum activity against other bacterial species, including Escherichia coli , Staphylococcus aureus , and Pseudomonas aeruginosa . The antimicrobial activity of VLX600 was abrogated by supplemental iron, indicating a mechanism dependent on iron chelation. VLX600 significantly reduced bacterial burdens and inflammation in a murine model of pulmonary M. abscessus infection. Additionally, synergistic effects were observed when VLX600 was combined with conventional antibiotics such as amikacin and clarithromycin in vitro . These findings highlight VLX600 as a promising candidate for repurposing as an antimicrobial agent against M. abscessus , warranting further clinical investigations. IMPORTANCE Mycobacterium abscessus is an opportunistic pathogen that commonly causes pulmonary infections in cystic fibrosis patients. These infections are notoriously difficult to treat due to high levels of antibiotic resistance of M. abscessus , resulting in low cure rates. In this study, we identified a novel antibiotic candidate, VLX600, through high-throughput screening of 3,200 clinical compounds and demonstrated that VLX600 inhibits the growth of M. abscessus by depriving it of ferric and ferrous ions. This study highlights the potential of iron chelators as antimicrobial agents against M. abscessus infections. Since iron is an essential nutrient for the growth of many bacteria, the use of iron chelators could be extended to other infectious diseases. We hope this research will inspire further studies aimed at developing iron chelators as a novel class of antimicrobial agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusMycobacterium Infections, NontuberculousAnti-Bacterial AgentsIron Chelating AgentsAntineoplastic AgentsAnimalsMicrobial Sensitivity TestsMiceHumansIronDisease Models, AnimalStaphylococcus aureusFemalePseudomonas aeruginosaDrug Synergism

Stichwörter der Autor:innen

Mycobacterium abscessusVLX600antibioticsdrug repositioningiron chelator

Substanzen

Anti-Bacterial AgentsIron Chelating AgentsIronAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul, Republic of Korea.
  • Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea.
  • Cancer Research Institute, College of Medicine, Seoul National University, Seoul, Republic of Korea.
  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Liver Research Institute, College of Medicine, Seoul National University, Seoul, Republic of Korea.

ORCID-Profile: Jaehun Oh, Nakwon Kwak, Bum-Joon Kim

Förderung

  • National Research Foundation of Korea (NRF)
  • SNUBH Research Fund

Zitieren

APA

Oh, J., Choi, S., Seo, H., Kim, D. H., Kim, H., Lee, D., Jang, J., Jung, S., Lee, J. Y., Kim, Z., Yim, J. J., Kwak, N., & Kim, B. J. (2025). VLX600, an anticancer iron chelator, exerts antimicrobial effects on Mycobacterium abscessus infections. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00719-25

Vancouver

Oh J, Choi S, Seo H, Kim DH, Kim H, Lee D, et al. VLX600, an anticancer iron chelator, exerts antimicrobial effects on Mycobacterium abscessus infections. Microbiology Spectrum. 2025. doi:10.1128/spectrum.00719-25

BibTeX
@article{Oh2025,
  author = {Oh, Jaehun and Choi, Seaone and Seo, Hyejun and Kim, Dong Hyun and Kim, Hyelin and Lee, Duhyung and Jang, Junghwa and Jung, Sangkwon and Lee, Ju-Young and Kim, Ziyun and Yim, Jae-Joon and Kwak, Nakwon and Kim, Bum-Joon},
  title = {VLX600, an anticancer iron chelator, exerts antimicrobial effects on Mycobacterium abscessus infections},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.00719-25}
}
Kostenlos starten →